Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 18Brain Neoplasms 9Glioblastoma 5Glioma 4Neoplasms 3Uterine Cervical Neoplasms 2Urogenital Diseases 2Disease 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostate Adenocarcinoma 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Follicular 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Lobular 1Breast Neoplasms 1

Interventions

Cyclophosphamide 153Dexamethasone 140Rituximab 83fludarabine 79Cytarabine 69Lenalidomide 68Bortezomib 64fludarabine phosphate 62Gemcitabine 62venetoclax 55Etoposide 53pembrolizumab 52pomalidomide 49Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × fluciclovine F-18 × Clear all
NCT03925675 2024-09-03

18F-Fluciclovine PET and Multiparametric MR Imaging

Loma Linda University

Phase 2 Withdrawn
CNS

Brain Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡